Multiple Myeloma

KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma 2:47
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma
Sergio Giralt • 17 Feb 2023
Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA 1:05
Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA
Hermann Einsele • 10 Feb 2023
The importance of managing hematologic toxicity associated with CAR-T therapy 2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe • 10 Feb 2023
Phase I study of CC-98633 in R/R multiple myeloma 2:45
Phase I study of CC-98633 in R/R multiple myeloma
Luciano Costa • 11 Dec 2022
Targeting neoantigens in multiple myeloma with CAR T-cell 5:56
Targeting neoantigens in multiple myeloma with CAR T-cell
Angela Krackhard • 6 Apr 2022
Updates in cell and gene therapy approvals 1:27
Updates in cell and gene therapy approvals
Bruce Levine • 27 Jan 2022
Exciting advances in CAR-T and TCR research 2:49
Exciting advances in CAR-T and TCR research
David Gilham • 22 Feb 2021
Challenges of CAR T-cell therapy for AML: is CD38 the answer? 6:10
Challenges of CAR T-cell therapy for AML: is CD38 the answer?
Lei Yu • 3 Jun 2021
Improving education in cell therapy 1:33
Improving education in cell therapy
Emanuele Ostuni • 12 Apr 2021
The European cell & gene therapy landscape 1:27
The European cell & gene therapy landscape
Paige Bischoff • 17 Mar 2021
A non-gene edited approach to allogeneic CAR-T development 2:21
A non-gene edited approach to allogeneic CAR-T development
Filippo Petti • 6 Apr 2021
Investigating allogeneic iNKT cell therapy 8:28
Investigating allogeneic iNKT cell therapy
Marc van Dijk • 23 Feb 2021
CT053, anti-GPC3 CAR-T and targeting solid tumors 4:15
CT053, anti-GPC3 CAR-T and targeting solid tumors
Hong Ma • 19 Feb 2021
Myeloma Patients Europe: collaborating on projects to benefit the myeloma community 2:49
Myeloma Patients Europe: collaborating on projects to benefit the myeloma community
Ananda Plate • 11 Feb 2021
CAR T-cells in myeloma: patients’ perspective 1:52
CAR T-cells in myeloma: patients’ perspective
Ananda Plate • 11 Feb 2021
The importance of partnering with patient organizations 3:48
The importance of partnering with patient organizations
Ananda Plate • 11 Feb 2021
The content of VJRegenMed is intended for healthcare professionals